Goldman Sachs Downgrades Vertex (VRTX) to Neutral
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/23/2026
- Wall St set to open lower as oil, bond yields tick up
- BTIG’s Krinsky warns 2000-like signals are mounting
- HSBC remains max bullish on stocks, tells investors to lean into tech
- Analyst explains why the midterm outcome is a “fundamental non-event”
- Oil holds near two-week lows while diesel cracks hit record
Vertex Pharma (VRTX) Sees Red-to-Green Reversal Following EPS
April 28, 2016 10:27 AM EDTVertex Pharma (NASDAQ: VRTX) reverse sharply off morning lows following earning after the close, which were seen as lackluster.
Shares are currently up 1% after opening down 3.9%.
... MoreVertex (VRTX) PT, Estimates Cut at Baird
April 28, 2016 7:45 AM EDTBaird analyst Brian Skorney lowered his price target on Vertex (NASDAQ: VRTX) to $128.00 (from $144.00) and Orkambi estimates on weak qua but maintained an Outperform rating.
Skorney commented, "Orkambi sales came in well below expectations that had already been revised significantly downwards over the last... More
Vertex Pharma (VRTX) Misses Q1 EPS by 20c; Increases 2016 KALYDECO Revenue Guidance
April 27, 2016 4:03 PM EDTVertex Pharma (NASDAQ: VRTX) reported Q1 EPS of $0.09, $0.20 worse than the analyst estimate of $0.29. Revenue for the quarter came in at $398.1 million versus the consensus estimate of $439.36 million.
First quarter 2016 cystic fibrosis product revenues of $394 million; $223 million for ORKAMBI® (lumacaftor/ivacaftor) and $171 million for KALYDECO®... More
